Navigation Links
Research sheds new light on heroin addiction
Date:5/14/2008

Researchers from the Howard Florey Institute in Melbourne have identified a factor that may contribute towards the development of heroin addiction by manipulating the adenosine A2A receptor, which plays a major role in the brains reward pathway.

Using mice specifically bred without the adenosine A2A receptor, Prof Andrew Lawrence and his team showed that these mice had a reduced desire to self-administer morphine; heroin is converted to morphine in the body. The mice also self-administered less morphine compared to control littermates, but did not develop tolerance to specific behavioural effects of morphine.

The researchers also found that the mice did not develop a conditioned place preference for the drug, indicating that drug-context associations are mediated in part by this receptor. In human terms, this equates to the associative memory of the environment where the drug is used.

Collectively, these findings strongly suggest that the adenosine A2A receptor is involved in regulating the reinforcing and motivational properties of opiates.

Prof Lawrence said this was the first study to show that the adenosine A2A receptor was implicated in self-motivation to take opiates such as heroin.

This receptor clearly plays a major role in opiate use and therefore abuse, as the mice were simply not interested in taking morphine despite it being freely available, he said.

Although the drug-taking effects and behaviours of these mice were diminished, they still relapsed into drug-seeking after a period of withdrawal.

This indicates that the adenosine A2A receptor has a role in the getting high aspects of addiction, but not in the adaptations that contribute to relapse after going cold turkey.

The results from this study reinforce that addiction is a highly complex brain disorder that will require a multi-pronged approach to treat.

Australia has over 50,000 heroin users. There are effective medical treatments available, such as methadone, buprenorphine and suboxone, as well as psychological interventions, but a better understanding of how heroin affects the brain could lead to improvements and broadening of these treatment options.

Drugs alone will not be the answer successful treatment of drug addiction will require a combination of drugs and psychotherapy, Prof Lawrence said.

Drugs alone will not be the answer successful treatment of drug addiction will require a combination of drugs and attention to social and psychological factors, Prof Lawrence said.

A number of major pharmaceutical companies are developing drugs that block the adenosine A2A receptor, so Prof Lawrences research provides even more evidence that this receptor is an important target for treating drug addiction.

Prof Lawrence said that drugs affecting the adenosine A2A receptor show preclinical promise to treat alcohol addiction.

Earlier this year we found that the adenosine A2A receptor interacts with the mGlu5 glutamate receptor found in the brains reward pathway to regulate drug-seeking. Consequently, a drug developed to target both these receptors could have an even better result in treating addiction, he added.


'/>"/>

Contact: Merrin Rafferty
merrin.rafferty@florey.edu.au
61-383-441-658
Research Australia
Source:Eurekalert

Related medicine news :

1. Stanford researchers find culprit in aging muscles that heal poorly
2. Children of depressed moms do better when dad is involved, SLU researcher finds
3. UCLA researchers identify markers that may predict diabetes in still-healthy people
4. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
5. New research shows how chronic stress worsens neurodegenerative disease course
6. New research explores newborn in-hospital weight loss
7. Research may unlock mystery of autisms origin in the brain
8. Bipolar disorder relapses halved by Melbourne researchers
9. HIVs impact in Zimbabwe explored in new research
10. U.S. Research Funding Continues to Flatten as U.S. Health Costs Climb - in August 31 Science
11. Cell that triggers symptoms in allergy attacks can also limit damage, Stanford researchers find
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... Viejo, CA (PRWEB) , ... July 20, 2017 , ... ... when placed between two clips in the FCPX timeline. This effect isolates horizontal and ... transition in this package contains either a rotating or flipping animation and can be ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... Houston, is pleased to announce their expansion to the Midwest with the establishment ... Alysse Hollis and Ronald Bell, and of counsels, John Peck and Robert Bruns, ...
(Date:7/20/2017)... ... ... Doctors on Liens, the leading network of medical providers working on a lien ... Horine, DC to their exclusive list of medical professionals. Horine Chiropractic is a unique ... clinic director and his son Dr. Lee Horine and daughter-in-law Dr. Natalie Horine serving ...
(Date:7/20/2017)... ... July 20, 2017 , ... The Dermatology Clinic announced today the addition ... BS in Biology from LSU, graduating summa cum laude. He attended Emory University School ... residency in St. Louis, Dr. Dunbar moved to New York to complete an AGCME-accredited ...
(Date:7/20/2017)... CA (PRWEB) , ... July 20, 2017 , ... ... of travel protection services since 2014, top travel insurance solution company VisitorsCoverage Inc. ... tools to sell all major international travel insurance products online, under their own ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... 2017  Sysmex America, Inc., a leading provider ... as well as middleware information systems technology, today ... quality assurance easier and more risk free than ... for the innovation that it delivers to the ... assurance processes to a new level with automated, ...
(Date:7/11/2017)... JERUSALEM , July 11, 2017 Oramed ... ), a clinical-stage pharmaceutical company focused on the development ... U.S. Food and Drug Administration (FDA) has agreed to ... successfully completed Phase IIb trial of its oral insulin ... The Phase IIb trial met primary and secondary endpoints ...
(Date:7/10/2017)... 2017 The Institute for In Vitro Sciences ... recipient of a VITROCELL® inhalation exposure system thanks to ... The device, which is designed to replace animals in ... cells to airborne test materials in an environment that ... system for testing combustible tobacco products, as well as ...
Breaking Medicine Technology: